Gelteq Limited announces production of 400,000 gel solution units, expected to boost sales in multiple regions starting January 2025.
Quiver AI Summary
Gelteq Limited, a company specializing in gel-based delivery solutions for various products, announced that it is commencing production of 400,000 units of its gel solution in November 2024, fulfilling orders for clients in the U.S. and Australia, with deliveries set for January 2025. These units will include nutraceutical products targeting sports, anti-aging, and weight loss markets. Co-Founder and CEO Nathan Givoni highlighted that this significant production run, shortly after their IPO, reflects successful execution of their plans and market validation of their technology. Additionally, Executive Chairman Simon Szewach noted the strengthened partnership with Monash Innovation Labs, which supports their capacity to meet client needs and ensure product quality. The company aims to expand its customer base and generate revenue in the near future.
Potential Positives
- Gelteq is set to enter production with 400,000 units of its gel solution, indicating robust demand and operational capabilities shortly after its IPO.
- The production run includes nutraceutical products targeting growth areas such as sports, anti-aging, and weight loss, enhancing the company's market reach.
- The company has strengthened its partnership with Monash Innovation Labs, which supports scalability and quality assurance in meeting client needs.
- Gelteq's ability to fulfill orders in multiple regions, including the U.S., Australia, UAE, and Asia, positions the company for significant revenue generation in the near term.
Potential Negatives
- The press release heavily relies on forward-looking statements, which create uncertainty about the company's future performance and may raise concerns among investors regarding the actual attainment of the outlined sales and production goals.
- Despite the announced production run, the company does not provide specifics about the financial health or past performance, which could lead to skepticism about the sustainability of the business model and market demand for its products.
- The mention of significant risks and uncertainties in forward-looking statements may indicate potential obstacles to fulfilling orders and achieving projected growth, which could affect investor confidence.
FAQ
What products is Gelteq producing?
Gelteq is producing gel solutions for prescription drugs, nutraceuticals, pet care, and other products.
When will Gelteq's gel solutions be available for sale?
Sales are expected to begin in January 2025 across the U.S., Australia, UAE, and Asia.
What recent development supports Gelteq's production scale?
The recent IPO has provided necessary capital to facilitate larger scale sales and production capacities.
How does Gelteq's technology improve drug delivery?
The unique gel formulation addresses issues like swallowing difficulties, taste, and dosage control for better experience.
Who are Gelteq's partners in production?
The company strengthened its partnership with Monash Innovation Labs to scale production and maintain product quality.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss.
Gelteq Co-Founder and CEO Nathan Givoni stated, “Our recent IPO was undertaken to provide the necessary capital and awareness of our technology to commence larger scale sales, whilst balancing our research and development activities. To see such volumes entering production so soon after the IPO is a testament to our team executing our plans, together with market validation on our gel-based technology. This production run demonstrates our ability to sell our products to end-users across the world and our ability to begin deriving revenues in the near term.”
Gelteq Co-Founder and Executive Chairman Simon Szewach stated, “Earlier this year, we strengthened our partnership with Monash Innovation Labs, which allows us to effectively scale and meet our client needs, while ensuring the quality of products. The orders connected to this production run are substantial and we believe that they represent the start of even larger volume orders to come.”
About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit
www.gelteq.com
.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its annual report for the year ended June 30, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Contact:
CORE IR
516-222-2560
[email protected]
